tetano
Editor, Senior Moderator
J Infect Chemother. 2017 Aug 3. pii: S1341-321X(17)30157-5. doi: 10.1016/j.jiac.2017.07.008. [Epub ahead of print]
[h=1]Adverse events of prophylactic anti-influenza agents in medical staffs.[/h] Kato H[SUP]1[/SUP], Hagihara M[SUP]1[/SUP], Kato Y[SUP]1[/SUP], Kurumiya A[SUP]1[/SUP], Takahashi T[SUP]1[/SUP], Sakata M[SUP]1[/SUP], Nishiyama N[SUP]1[/SUP], Asai N[SUP]1[/SUP], Koizumi Y[SUP]1[/SUP], Furui T[SUP]1[/SUP], Yamagishi Y[SUP]1[/SUP], Mikamo H[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We undertook a survey to evaluate the compliance and the tolerability of oseltamivir and zanamivir when they were used as post-exposure prophylaxis among the medical staffs in the 2014-2015 seasons to understand a characteristic of adverse events caused by anti-influenza (flu) agents.
[h=4]MATERIALS AND METHODS:[/h] During the study period, 540 medical staffs received oseltamivir (75 mg twice a day for 5 days) or zanamivir (twice a day for 5 days) as post-exposure prophylaxis of influenza, respectively.
[h=4]RESULTS:[/h] Four hundred eleven medical staffs of 540 medical staffs (76.1%) provided responses to questionnaire investigations. The adverse events caused by oseltamivir were reported by 86 of 382 medical staffs (22.5%). The most frequent adverse events were gastrointestinal adverse events (13.4%), followed by systemic and local diseases (11.8%), diseases of the nervous system (7.9%) and neuropsychiatric adverse events (0.5%). On the other hand, adverse events caused by zanamivir were reported by one (3.4%) of 29 medical staffs.
[h=4]CONCLUSION:[/h] Our survey revealed that 22.5% subjects experienced any adverse events due to oseltamivir. And the regimen showed low compliance than we expected. On the other hands, zanamivir showed high adherence with lower incidence of adverse events.
Copyright ? 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Flu; Oseltamivir; Outbreak; Prophylaxis; Zanamivir
PMID: 28781099 DOI: 10.1016/j.jiac.2017.07.008
[h=1]Adverse events of prophylactic anti-influenza agents in medical staffs.[/h] Kato H[SUP]1[/SUP], Hagihara M[SUP]1[/SUP], Kato Y[SUP]1[/SUP], Kurumiya A[SUP]1[/SUP], Takahashi T[SUP]1[/SUP], Sakata M[SUP]1[/SUP], Nishiyama N[SUP]1[/SUP], Asai N[SUP]1[/SUP], Koizumi Y[SUP]1[/SUP], Furui T[SUP]1[/SUP], Yamagishi Y[SUP]1[/SUP], Mikamo H[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We undertook a survey to evaluate the compliance and the tolerability of oseltamivir and zanamivir when they were used as post-exposure prophylaxis among the medical staffs in the 2014-2015 seasons to understand a characteristic of adverse events caused by anti-influenza (flu) agents.
[h=4]MATERIALS AND METHODS:[/h] During the study period, 540 medical staffs received oseltamivir (75 mg twice a day for 5 days) or zanamivir (twice a day for 5 days) as post-exposure prophylaxis of influenza, respectively.
[h=4]RESULTS:[/h] Four hundred eleven medical staffs of 540 medical staffs (76.1%) provided responses to questionnaire investigations. The adverse events caused by oseltamivir were reported by 86 of 382 medical staffs (22.5%). The most frequent adverse events were gastrointestinal adverse events (13.4%), followed by systemic and local diseases (11.8%), diseases of the nervous system (7.9%) and neuropsychiatric adverse events (0.5%). On the other hand, adverse events caused by zanamivir were reported by one (3.4%) of 29 medical staffs.
[h=4]CONCLUSION:[/h] Our survey revealed that 22.5% subjects experienced any adverse events due to oseltamivir. And the regimen showed low compliance than we expected. On the other hands, zanamivir showed high adherence with lower incidence of adverse events.
Copyright ? 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Flu; Oseltamivir; Outbreak; Prophylaxis; Zanamivir
PMID: 28781099 DOI: 10.1016/j.jiac.2017.07.008